This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Patient Safety/ Medical Error  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Revascularization  • Alert me on articles by topic

The MEND-CABG II Randomized Clinical Trial

MEND-CABG II Investigators*

JAMA. 2008;299(15):1777-1787. Published online April 1, 2008 (doi:10.1001/jama.299.15.joc80027).

Context  Coronary artery bypass graft (CABG) surgery is frequently performed and effective; however, perioperative complications related to ischemia-reperfusion injury, including myocardial infarction (MI), remain common and result in significant morbidity and mortality. MC-1, a naturally occurring pyridoxine metabolite and purinergic receptor antagonist, prevents cellular calcium overload and may reduce ischemia-reperfusion injury. Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery.

Objective  To assess the efficacy and safety of MC-1 administered immediately before and for 30 days after surgery in patients undergoing CABG surgery.

Design, Setting, and Participants  The MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial, with 3023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass enrolled between October 2006 and September 2007 at 130 sites in Canada, the United States, and Germany.

Interventions  Patients received either MC-1, 250 mg/d (n = 1519), or matching placebo (n = 1504) immediately before and for 30 days after CABG surgery.

Main Outcome Measures  The primary efficacy outcome was cardiovascular death or nonfatal MI, defined as a creatine kinase (CK) MB fraction of at least 100 ng/mL or new Q waves through postoperative day 30.

Results  The primary efficacy outcome occurred in 140 of 1510 patients (9.3%) in the MC-1 group and 133 of 1486 patients (9.0%) in the placebo group (risk ratio, 1.04; 95% confidence interval, 0.83-1.30; P = .76). All-cause mortality was higher among patients assigned to MC-1 than placebo at 4 days (1.0% vs 0.3%; P = .03) but was similar at 30 days (1.9% vs 1.5%; P = .44). There was no difference in the 8- to 24-hour CK-MB area under the curve between the MC-1 and placebo groups (median, 270 [interquartile range, 175-492] vs 268 [interquartile range, 170-456] hours x ng/mL; P = .11).

Conclusion  In this population of intermediate- to high-risk patients undergoing CABG surgery, MC-1 did not reduce the composite of cardiovascular death or nonfatal MI.

Trial Registration  clinicaltrials.gov Identifier: NCT00402506

Authors/MEND-CABG II Writing Group: John H. Alexander , MD, MHS , Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina; Robert W. Emery Jr , MD , Minnesota Heart and Vascular Center, Edina, Minnesota; Michel Carrier , MD , Montreal Heart Institute, Montreal, Quebec, Canada; Stephen J. Ellis , PhD , Duke Clinical Research Institute, Durham, North Carolina; Rajendra H. Mehta , MD, MHS , Duke Clinical Research Institute, Durham, North Carolina; Vic Hasselblad , PhD , Duke Clinical Research Institute, Durham, North Carolina; Philippe Menasche , MD , Hospital European George Pompidou, Paris, France; Ahmad Khalil , MD, PhD , Medicure International Inc, Winnipeg, Manitoba, Canada; Robert Cote , MD , Montreal Heart Institute, Montreal, Quebec, Canada; Elliott Bennett-Guerrero , MD , Duke University Medical Center, Durham, North Carolina; Michael J. Mack , MD , Cardiothoracic Surgery Associates of North Texas, Dallas; Gerhard Schuler , MD , University of Leipzig, Leipzig, Germany; Robert A. Harrington , MD , Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina; Jean-Claude Tardif , MD , Montreal Heart Institute, Montreal, Quebec, Canada.

RELATED ARTICLE

Coronary Artery Bypass Grafting
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2008;299(15):1856.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

All you need to read in the other general journals
BMJ 2008;336:914-915.
FULL TEXT  

MC-1 Fails to Improve Outcomes of Coronary Artery Bypass Grafting
Journal Watch Cardiology 2008;2008:3-3.
FULL TEXT